Regeneron/Bayer Announce Positive VEGF Trap-Eye Data In A Second Eye Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Application to treat central retinal vein occlusion may be in the works to follow soon after wet AMD filing set for first half of 2011.
You may also be interested in...
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.
Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year
If the ophthalmic product wins priority review, Roche could see competition for Lucentis in wet AMD by the fall.